Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: Data from a randomized, controlled, open-label trial

Arthritis and Rheumatology

Volumn 66, Issue 8, 2014, Pages 2015-2025

  Sellam, Jérémie ^a   Marion Thore, Sandrine ^b,l   Dumont, Florent ^c   Jacques, Sébastien ^c   Garchon, Henri Jean ^b,d   Rouanet, Stéphanie ^e   Taoufik, Yassine ^f   Hendel Chavez, Houria ^f   Sibilia, Jean ^g   Tebib, Jacques ^h   Le Loët, Xavier ⁱ   Combe, Bernard ^j   Dougados, Maxime ^k   Mariette, Xavier ^f   Chiocchia, Gilles ^b,d  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM U 987   (France)

^c INSTITUT COCHIN   (France)

^d LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^e Roche ^*  (France)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^h CENTRE HOSPITALIER LYON SUD   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j LAPEYRONIE HOSPITAL   (France)

^k UNIVERSITÉ PARIS DESCARTES   (France)

^l UNIVERSITY OF LIMOGES   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IFIH1 PROTEIN; IFITM1 PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 11; INTERLEUKIN 29; INTERLEUKIN 33; ISG20 PROTEIN; METHOTREXATE; PHF11 PROTEIN; PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RITUXIMAB; SP100 PROTEIN; STAT5A PROTEIN; TRIM22 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY SCORE; DISEASE DURATION; DOWN REGULATION; DRUG EFFICACY; DRUG TOLERANCE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION PROFILING; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; TRANSCRIPTOMICS; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; TRANSCRIPTOME;

EID: 84905007989     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38671     Document Type: Article

References (32)

1. Choy EH, Kavanaugh AF, Jones SA,. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013; 9: 154-63.
2. Edwards JC, Cambridge G,. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 205-11.
3. Panayi GS,. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?. Rheumatology (Oxford) 2005; 44 Suppl 2: ii3-7.
4. Martinez A, Varade J, Lamas JR, Fernandez-Arquero M, Jover JA, de la Concha EG, et al. Association of the IFIH1-GCA-KCNH7 chromosomal region with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 137-8.
5. Sibilia J, Gottenberg JE, Mariette X,. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008; 75: 526-32.
6. Fu YX, Huang G, Wang Y, Chaplin DD,. B lymphocytes induce the formation of follicular dendritic cell clusters in a lymphotoxin α-dependent fashion. J Exp Med 1998; 187: 1009-18.
7. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 143-50.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
9. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63: 933-8.
10. Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2011; 63: 3692-701.
11. Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, et al. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2013; 65: 2253-61.
12. Vital EM, Dass S, Rawstron AC, Buch MH, Goeb V, Henshaw K, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010; 62: 1273-9.
13. Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum 2010; 62: 3607-14.
14. Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, et al. Interferon type I signature may predict non response upon rituximab in rheumatoid arthritis patients. Arthritis Res Ther 2012; 14: R95.
15. Julia A, Barcelo M, Erra A, Palacio C, Marsal S,. Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells. Pharmacogenomics 2009; 10: 1697-708.
16. Owczarczyk K, Lal P, Abbas AR, Wolslegel K, Holweg CT, Dummer W, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 2011; 3: 101ra92.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
18. Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J, et al. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis 2013. In press.
19. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009; 68: 954-60.
20. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40.
21. Tibshirani R, Hastie T, Narasimhan B, Chu G,. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002; 99: 6567-72.
22. Roman-Blas JA, Jimenez SA,. NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2006; 14: 839-48.
23. Perlman H, Liu H, Georganas C, Koch AE, Shamiyeh E, Haines GK III, et al. Differential expression pattern of the antiapoptotic proteins, Bcl-2 and FLIP, in experimental arthritis. Arthritis Rheum 2001; 44: 2899-908.
24. Palmer G, Gabay C,. Interleukin-33 biology with potential insights into human diseases. Nat Rev Rheumatol 2011; 7: 321-9.
25. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA,. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J Immunol 2003; 171: 5042-50.
26. Veninga H, Becker S, Hoek RM, Wobus M, Wandel E, van der Kaa J, et al. Analysis of CD97 expression and manipulation: antibody treatment but not gene targeting curtails granulocyte migration. J Immunol 2008; 181: 6574-83.
27. Yu S, Gao B, Duan Z, Xu W, Xiong S,. Identification of tripartite motif-containing 22 (TRIM22) as a novel NF-κB activator. Biochem Biophys Res Commun 2011; 410: 247-51.
28. O'Donnell K, Harkes IC, Dougherty L, Wicks IP,. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. Am J Pathol 1999; 154: 1171-80.
29. Lopez-Arbesu R, Ballina-Garcia FJ, Alperi-Lopez M, Lopez-Soto A, Rodriguez-Rodero S, Martinez-Borra J, et al. MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. Rheumatology (Oxford) 2007; 46: 426-30.
30. Szostecki C, Will H, Netter HJ, Guldner HH,. Autoantibodies to the nuclear Sp100 protein in primary biliary cirrhosis and associated diseases: epitope specificity and immunoglobulin class distribution. Scand J Immunol 1992; 36: 555-64.
31. Reynier F, Petit F, Paye M, Turrel-Davin F, Imbert PE, Hot A, et al. Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. PLoS One 2011; 6: e24828.
32. Verweij CL, Vosslamber S,. New insight in the mechanism of action of rituximab: the interferon signature towards personalized medicine. Discov Med 2011; 12: 229-36.